Company intelligence
Neovii
Biotechnology
Rapperswil, CH
125 employees
Founded 2003
1 public signals
About Neovii
Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology. Our lead product, Grafalon®, has been used for over 30 years to treat patients and is available in more than 40 countries world wide. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.
Verified activity
Signals from Neovii
1 published signal